List of Repurposed/505(b)(2) Drugs Companies with Phase 2 Active Clinical Trial - 12

Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors. The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury. Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. • Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell. • Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. • DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys. Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.

Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.

Eusol Biotech was founded in March 2005 in Taipei, Taiwan. The company is involved in the R&D and GMP process development of recombinant human acid fibroblast.

Frantz Viral Therapeutics is focused on the development of topical treatments for pre-cancerous conditions related to human papillomavirus (HPV) infections in the cervix, vulva, and anus.

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. We have a lead asset – ISLA-101 - that was initially developed by our wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.

Founded in 2008, S1 Biopharma is developing first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men. The company’s non-hormonal therapies work uniquely by restoring the natural balance of neurotransmitters in the brain. Since our company’s inception, we have been committed to innovation, integrity, the use of the highest quality science and a deep understanding of the biology underlying these disorders to develop effective treatments with safety as a priority. See our social media community guidelines at http://bit.ly/1kLpD6M

SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder and epilepsy.

Starton Therapeutics is a clinical-stage biotechnology company that is transforming standard-of-care therapies with proprietary dermal technology, so people with cancer can receive continuous treatment to live better, longer. Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are the most common blood cancers in the United States. There is no treatment to help people with CLL to stay in remission, and while advances in treatment have provided people with MM a multitude of treatment options, they struggle with long-term tolerance of high doses, which may be more effective but come with a multitude of side effects. Starton's team of some of the best in clinical development and hematology/oncology have come together to change the fate for people struggling with the impact of their diseases. If dose-related side effects can be reduced and people can tolerate maintenance therapy for decades to help stay in remission, these cancers – which were previously a death sentence – would become more akin to chronic diseases, with a long lifespan and healthy quality of life. Starton is one of the few life sciences companies funded exclusively by individual investors. We have a business model that is lower risk, faster to market and less capital intensive than biotech companies developing medicines from scratch.

We Specialize in Urology and Women’s Health Care.Pain, urgency, frequency. Every day, urologic disorders continue to affect the lives of people all around us. Vaneltix is focused on providing immediate relief for patients suffering from Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), a disease of the lower urinary tract that predominantly affects women.

Woolsey Pharmaceuticals is a biopharmaceutical company that provides therapeutics common diseases.